Five things for pharma marketers to know: Tuesday, November 7, 2017
Senator investigates Alkermes’ opioid-marketing tactics; FDA approves Roche cancer drugs; CVS to launch next-day delivery nationwide
Opioids
CDC tells opioid addiction stories with message: ‘It only takes a little to lose a lot’
The CDC has launched the first wave of its awareness campaign about prescription opioids.
Five things for pharma marketers to know: Tuesday, October 31, 2017
Pfizer Q3 revenue driven by Prevnar sales; President Trump’s opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Five things for pharma marketers to know: Thursday, October 26, 2017
Non-profit challenges Gilead’s Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
Five things for pharma marketers to know: Monday, October 16, 2017
FDA briefing document affirms diabetes drug’s efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified
Five things for pharma marketers to know: Thursday, October 5, 2017
Cigna will no longer cover OxyContin; the AMA no longer supports price-fixing to lower drug prices; Gottlieb is not in favor of ‘right-to-try’ laws
Five things for pharma marketers to know: Monday, October 2, 2017
The FDA tells 75 opioid drugmakers to fund training efforts; epilepsy drug reduces seizure frequency; FDA approves Novo’s fast-acting mealtime insulin
Five things for pharma marketers to know: Monday, September 25, 2017
The FDA declines to approve an opioid and a treatment for rheumatoid arthritis; KKR closes WebMD buyout; 60% of teens have received the HPV vaccine
Five things for pharma marketers to know: Friday, September 22, 2017
Express Scripts’ Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts
Five things for pharma marketers to know: Monday, September 18, 2017
Insurers rarely require prior authorization for opioids; court of appeals voids J&J win in Advil ads suit; new California law to address drug pricing
